Oseltamivir Phosphate NDC 72303-0851

NDC codes

FDA NDC Directory

Product NDC (as listed)72303-0851Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72303-0851Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72303-0851-1	72303085101	1 BOTTLE, PLASTIC in 1 CARTON (72303-0851-1) / 60 mL in 1 BOTTLE, PLASTICMarketed from Mar 25, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oseltamivir Phosphate
Generic name (nonproprietary): oseltamivir phosphate
Active ingredients: Oseltamivir phosphate — 6 mg/mL
Dosage form: Suspension
Route: Oral
Labeler: HEC Pharm USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213594
Marketing start: Mar 25, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Neuraminidase Inhibitors (Mechanism)
Identifiers: Product ID 72303-0851_533e2670-7504-ecb5-e063-6294a90a5c19SPL ID 533e2670-7504-ecb5-e063-6294a90a5c19SPL set ID 4dd9214a-6b7f-efe9-e063-6294a90ac4fbRxCUI 1115698UNII 4A3O49NGEZUPC 0372303085115
Pharmacologic class: Neuraminidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472303085101 followed by a unit qualifier and the quantity

Package 72303-0851-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 1, 2026.

Indications (excerpt from the label)

Oseltamivir phosphate for oral suspension is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use : Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) 1.1 Treatment of Influenza Oseltamivir phosphate for oral suspension is …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213594

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213594
Product	Strength	Form · route	Labeler	Product NDC
Oseltamivir Phosphate	Oseltamivir phosphate 6 mg/mL	SuspensionOral	A-S Medication Solutions	50090-7346
Oseltamivir Phosphate	Oseltamivir phosphate 6 mg/mL	SuspensionOral	Lannett Company, Inc.	0527-5137